Pleuritis carcinomatosa

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 4, 2011, Pages 524-527

  Miyanaga, Akihiko ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Malignant pleural effusion; Pleurodesis; Sclerosing agents

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; BLEOMYCIN; CISPLATIN; ETOPOSIDE; PICIBANIL; TALC; TETRACYCLINE;

ARTICLE; CARCINOMATOUS PLEURISY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PLEURA DISEASE; PLEURA EFFUSION; PLEURODESIS; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; THORACOSCOPY; THORAX DRAINAGE;

EID: 79960623450     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Herrstedt J, Clementsen P and Hansen OP: Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer 28A: 1070-1073, 1992.
2. Sørensen PG, Svendsen TL and Enk B: Treatment of malignant pleural effusion with drainage, with and without instillation of talc. Eur J Respir Dis 65: 131-135, 1984. (Pubitemid 14188709)
3. Zaloznik AJ, Oswald SG and Langin M: Intrapleural tetracycline in malignant pleural effusions. A randomized study. Cancer 51: 752-755, 1983. (Pubitemid 13137698)
4. Tan C, Sedrakyan A, Browne J, et al: The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 29: 829-838, 2006.
5. Dryzer SR, Allen ML, Strange C, et al: A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 104: 1763-1766, 1993. (Pubitemid 23360108)
6. Ruckdeschel JC, Moores D, Lee JY, et al: Intrapleuraltherapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest 100: 1528-1535, 1991.
7. Hartman DL, Gaither JM, Kesler KA, et al: Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 105: 743-747, 1993.
8. Shaw P and Agarwal R: Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 1: CD002916, 2004.
9. Dresler CM, Olak J, Herndon JE 2nd, et al: Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127: 909-915, 2005. (Pubitemid 40775523)
10. Janssen JP, Collier G, Astoul P, et al: Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369: 1535-1539, 2007. (Pubitemid 46670303)
11. Yoshida K, Sugiura T, Takifuji N, et al: Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 58: 362-368, 2007. (Pubitemid 350051515)
12. Seto T, Ushijima S, Yamamoto H, et al: Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancen a multi-institutional phase II trial. Br J Cancer 95: 717-721, 2006. (Pubitemid 44373487)
13. North SA, Au HJ, Halls SB, et al: A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion. Chest 123: 822-827, 2003. (Pubitemid 36315499)
14. Pass HI, Carbone DP, Minna JD, et al: Lung Cancer Principles and Practice (4th ed), Lippincott Williams & Wilkins, Philadelphia, 2010, p 905.